Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFG |
Texto Completo: | http://repositorio.bc.ufg.br/tede/handle/tede/6958 |
Resumo: | Cardiovascular diseases are among the diseases of higher mortality rates in Brazil and worldwide . In contrast, it is reducing deaths of cardiovascular diseases due, in large part, to the production of drugs that can control their risk factors, but the wide reporting of side effects and contraindications persist and interfere negatively in the context of mortality these diseases. In this point, it is necessary to develop new drugs more effective and safer. The process of development of new drug requires numerous preclinical studies that generate information regarding safety profile in vivo determinants for making the decision to start clinical trials. Although it is a conventional practice, the use of animals in scientific research should happen consciously, always considering the ethical issues of animal experimentation. In this study, we investigated the basal cytotoxicity against 3T3 cells of seven pyrazole compounds (LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, and LQFM023 LQFM024) and classified then in GHS system. Whereas the compound LQFM021 proved to be the most effective in the tests performed in parallel pharmacodynamic study, we investigated whether acute oral toxicity, subacute and mutagenicity of this compound. The results showed that the compounds have low cytotoxicity profile in basal cell line (3T3). The estimated LD50 values for compounds LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, and LQFM023 LQFM024 were 548, 551, 568, 533, 457, 482, 565 mg / kg, respectively. The compounds LQFM020, LQFM023 LQFM024 were classified in category 5 GHS system and LQFM021 was classified in category 4. The subacute toxicological research for 28 days LQFM021 the compound showed that this compound did not affect the metabolic, hematological and biochemical animal parameters in any of the doses of exposure However, the histopathology indicated hepatotoxic and nephrotoxic potential of this compound and interference in the process of hematopoiesis, but did not indicate mutagenic potential. . Given the above, we conside |
id |
UFG-2_99e3bef40ff59df7d8c6510bab87d710 |
---|---|
oai_identifier_str |
oai:repositorio.bc.ufg.br:tede/6958 |
network_acronym_str |
UFG-2 |
network_name_str |
Repositório Institucional da UFG |
repository_id_str |
|
spelling |
Valadares, Marize Camposhttp://lattes.cnpq.br/6157755243167018Valadares, Marize CamposCunha, Luiz CarlosCosta, Renata Mazaro ehttp://lattes.cnpq.br/1673831876703835Moura, Soraia Santana de2017-03-20T13:38:54Z2012-11-28MOURA, S. S. Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular. 2012. 119 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Goiás, Goiânia, 2012.http://repositorio.bc.ufg.br/tede/handle/tede/6958Cardiovascular diseases are among the diseases of higher mortality rates in Brazil and worldwide . In contrast, it is reducing deaths of cardiovascular diseases due, in large part, to the production of drugs that can control their risk factors, but the wide reporting of side effects and contraindications persist and interfere negatively in the context of mortality these diseases. In this point, it is necessary to develop new drugs more effective and safer. The process of development of new drug requires numerous preclinical studies that generate information regarding safety profile in vivo determinants for making the decision to start clinical trials. Although it is a conventional practice, the use of animals in scientific research should happen consciously, always considering the ethical issues of animal experimentation. In this study, we investigated the basal cytotoxicity against 3T3 cells of seven pyrazole compounds (LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, and LQFM023 LQFM024) and classified then in GHS system. Whereas the compound LQFM021 proved to be the most effective in the tests performed in parallel pharmacodynamic study, we investigated whether acute oral toxicity, subacute and mutagenicity of this compound. The results showed that the compounds have low cytotoxicity profile in basal cell line (3T3). The estimated LD50 values for compounds LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, and LQFM023 LQFM024 were 548, 551, 568, 533, 457, 482, 565 mg / kg, respectively. The compounds LQFM020, LQFM023 LQFM024 were classified in category 5 GHS system and LQFM021 was classified in category 4. The subacute toxicological research for 28 days LQFM021 the compound showed that this compound did not affect the metabolic, hematological and biochemical animal parameters in any of the doses of exposure However, the histopathology indicated hepatotoxic and nephrotoxic potential of this compound and interference in the process of hematopoiesis, but did not indicate mutagenic potential. . Given the above, we consideAs doenças cardiovasculares estão entre as doenças de maior letalidade no Brasil e no mundo. Em contrapartida, vê-se um quadro redução das mortes atribuídas às enfermidades cardiovasculares devido, em grande parte, à produção de medicamentos capazes de controlar seus fatores de risco, porém, o vasto relato de efeitos colaterais e contraindicações persistem e interferem negativamente no quadro de morbimortalidade dessas doenças. Neste sentindo, é imprescindível buscar novos fármacos mais efetivos e seguros. O processo de desenvolvimento de um novo fármaco exige numerosos estudos pré-clínicos que geram informações quanto ao seu perfil de segurança in vivo, determinantes para a tomada de decisão de se iniciar os estudos clínicos. Embora seja uma prática convencional, o uso de animais em pesquisas científicas deve ocorrer de forma consciente, considerando sempre as questões éticas de experimentação animal. Neste trabalho, investigou-se a citotoxicidade basal frente as células 3T3 de sete compostos pirazolínicos (LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, LQFM023 e LQFM024) e suas classificações no sistema GHS. Considerando que o composto LQFM021 demonstrou ser o mais eficaz nos ensaios realizados em paralelo de farmacodinâmica, investigou-se toxicidade oral aguda, subaguda e mutagenicidade do composto. Os resultados mostraram que os compostos possuem perfil de baixa citotoxicidade em linhagem basal (3T3). Os valores de DL50 estimados para os compostos LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, LQFM023 e LQFM024 foram 548, 551, 568, 533, 457, 482, 565 mg/kg, respectivamente. Os compostos LQFM020, LQFM023 e LQFM024 foram classificadas na categoria 5 do sistema GHS e o composto LQFM021 foi classificado na categoria 4. A investigação toxicológica subaguda por 28 dias do composto LQFM021 mostrou que este composto não interferiu nos parâmetros metabólico, hematológico e bioquímico dos animais em nenhuma das doses de exposição. No entanto, o estudo histopatológico indicou potencial nefrotóxico e hepatotóxico deste composto e interferência sobre o processo de hematopoiese, entretanto, não apresentou potencial mutagênico. Diante do exposto, consideramos que o composto LQFM021 apresenta um baixo perfil de toxicidade e os estudos de continuidade devem ser encorajados.Submitted by Erika Demachki (erikademachki@gmail.com) on 2017-03-16T21:37:33Z No. of bitstreams: 2 Dissertação - Soraia Santana de Moura - 2012.pdf: 3848911 bytes, checksum: 6c2c1f811c32328fc8cdb22d9edaf90a (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-03-20T13:38:54Z (GMT) No. of bitstreams: 2 Dissertação - Soraia Santana de Moura - 2012.pdf: 3848911 bytes, checksum: 6c2c1f811c32328fc8cdb22d9edaf90a (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Made available in DSpace on 2017-03-20T13:38:54Z (GMT). No. of bitstreams: 2 Dissertação - Soraia Santana de Moura - 2012.pdf: 3848911 bytes, checksum: 6c2c1f811c32328fc8cdb22d9edaf90a (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2012-11-28Fundação de Apoio à Pesquisa - FUNAPEConselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPqCoordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESFinanciadora de Estudos e Projetos- Finepapplication/pdfporUniversidade Federal de GoiásPrograma de Pós-graduação em Ciências da Saúde (FM)UFGBrasilFaculdade de Medicina - FM (RG)http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessAnálise toxicológicaDerivado pirazolínicoFármaco cardiovascularToxicological analysisPyrazole derivativeCardiovascular drugFARMACIA::ANALISE TOXICOLOGICAAvaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascularAssessment of acute and subacute toxicity of a new cardiovascular drug candidate prototypeinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesis-10068643126177453106006006006006006006001545772475950486338-742516873750689813-8644727573657825680-25559114369857136592075167498588264571-8370082027677193632reponame:Repositório Institucional da UFGinstname:Universidade Federal de Goiás (UFG)instacron:UFGLICENSElicense.txtlicense.txttext/plain; charset=utf-82165http://repositorio.bc.ufg.br/tede/bitstreams/4cff681b-f718-47b0-9b8c-74a7371e2fda/downloadbd3efa91386c1718a7f26a329fdcb468MD51CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://repositorio.bc.ufg.br/tede/bitstreams/c3d015cc-5a84-4b7b-8d1c-b030959b0c79/download4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-80http://repositorio.bc.ufg.br/tede/bitstreams/22e35d1d-a4fb-4bd0-951c-72f3cd13f669/downloadd41d8cd98f00b204e9800998ecf8427eMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-80http://repositorio.bc.ufg.br/tede/bitstreams/bb8001ed-d48c-4484-b66d-f556f827e632/downloadd41d8cd98f00b204e9800998ecf8427eMD54ORIGINALDissertação - Soraia Santana de Moura - 2012.pdfDissertação - Soraia Santana de Moura - 2012.pdfapplication/pdf3848911http://repositorio.bc.ufg.br/tede/bitstreams/3ba90b6d-74ad-4dfb-8112-f3820af79f14/download6c2c1f811c32328fc8cdb22d9edaf90aMD55tede/69582017-03-20 10:38:55.01http://creativecommons.org/licenses/by-nc-nd/4.0/Acesso Abertoopen.accessoai:repositorio.bc.ufg.br:tede/6958http://repositorio.bc.ufg.br/tedeRepositório InstitucionalPUBhttp://repositorio.bc.ufg.br/oai/requesttasesdissertacoes.bc@ufg.bropendoar:2017-03-20T13:38:55Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)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 |
dc.title.por.fl_str_mv |
Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular |
dc.title.alternative.eng.fl_str_mv |
Assessment of acute and subacute toxicity of a new cardiovascular drug candidate prototype |
title |
Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular |
spellingShingle |
Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular Moura, Soraia Santana de Análise toxicológica Derivado pirazolínico Fármaco cardiovascular Toxicological analysis Pyrazole derivative Cardiovascular drug FARMACIA::ANALISE TOXICOLOGICA |
title_short |
Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular |
title_full |
Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular |
title_fullStr |
Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular |
title_full_unstemmed |
Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular |
title_sort |
Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular |
author |
Moura, Soraia Santana de |
author_facet |
Moura, Soraia Santana de |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Valadares, Marize Campos |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/6157755243167018 |
dc.contributor.referee1.fl_str_mv |
Valadares, Marize Campos |
dc.contributor.referee2.fl_str_mv |
Cunha, Luiz Carlos |
dc.contributor.referee3.fl_str_mv |
Costa, Renata Mazaro e |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/1673831876703835 |
dc.contributor.author.fl_str_mv |
Moura, Soraia Santana de |
contributor_str_mv |
Valadares, Marize Campos Valadares, Marize Campos Cunha, Luiz Carlos Costa, Renata Mazaro e |
dc.subject.por.fl_str_mv |
Análise toxicológica Derivado pirazolínico Fármaco cardiovascular |
topic |
Análise toxicológica Derivado pirazolínico Fármaco cardiovascular Toxicological analysis Pyrazole derivative Cardiovascular drug FARMACIA::ANALISE TOXICOLOGICA |
dc.subject.eng.fl_str_mv |
Toxicological analysis Pyrazole derivative Cardiovascular drug |
dc.subject.cnpq.fl_str_mv |
FARMACIA::ANALISE TOXICOLOGICA |
description |
Cardiovascular diseases are among the diseases of higher mortality rates in Brazil and worldwide . In contrast, it is reducing deaths of cardiovascular diseases due, in large part, to the production of drugs that can control their risk factors, but the wide reporting of side effects and contraindications persist and interfere negatively in the context of mortality these diseases. In this point, it is necessary to develop new drugs more effective and safer. The process of development of new drug requires numerous preclinical studies that generate information regarding safety profile in vivo determinants for making the decision to start clinical trials. Although it is a conventional practice, the use of animals in scientific research should happen consciously, always considering the ethical issues of animal experimentation. In this study, we investigated the basal cytotoxicity against 3T3 cells of seven pyrazole compounds (LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, and LQFM023 LQFM024) and classified then in GHS system. Whereas the compound LQFM021 proved to be the most effective in the tests performed in parallel pharmacodynamic study, we investigated whether acute oral toxicity, subacute and mutagenicity of this compound. The results showed that the compounds have low cytotoxicity profile in basal cell line (3T3). The estimated LD50 values for compounds LQFM011, LQFM012, LQFM020, LQFM021, LQFM022, and LQFM023 LQFM024 were 548, 551, 568, 533, 457, 482, 565 mg / kg, respectively. The compounds LQFM020, LQFM023 LQFM024 were classified in category 5 GHS system and LQFM021 was classified in category 4. The subacute toxicological research for 28 days LQFM021 the compound showed that this compound did not affect the metabolic, hematological and biochemical animal parameters in any of the doses of exposure However, the histopathology indicated hepatotoxic and nephrotoxic potential of this compound and interference in the process of hematopoiesis, but did not indicate mutagenic potential. . Given the above, we conside |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012-11-28 |
dc.date.accessioned.fl_str_mv |
2017-03-20T13:38:54Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
MOURA, S. S. Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular. 2012. 119 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Goiás, Goiânia, 2012. |
dc.identifier.uri.fl_str_mv |
http://repositorio.bc.ufg.br/tede/handle/tede/6958 |
identifier_str_mv |
MOURA, S. S. Avaliação da toxicidade aguda e subaguda de um novo protótipo candidato a fármaco cardiovascular. 2012. 119 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Goiás, Goiânia, 2012. |
url |
http://repositorio.bc.ufg.br/tede/handle/tede/6958 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.program.fl_str_mv |
-1006864312617745310 |
dc.relation.confidence.fl_str_mv |
600 600 600 600 600 600 600 |
dc.relation.department.fl_str_mv |
1545772475950486338 |
dc.relation.cnpq.fl_str_mv |
-742516873750689813 |
dc.relation.sponsorship.fl_str_mv |
-8644727573657825680 -2555911436985713659 2075167498588264571 -8370082027677193632 |
dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Goiás |
dc.publisher.program.fl_str_mv |
Programa de Pós-graduação em Ciências da Saúde (FM) |
dc.publisher.initials.fl_str_mv |
UFG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Faculdade de Medicina - FM (RG) |
publisher.none.fl_str_mv |
Universidade Federal de Goiás |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFG instname:Universidade Federal de Goiás (UFG) instacron:UFG |
instname_str |
Universidade Federal de Goiás (UFG) |
instacron_str |
UFG |
institution |
UFG |
reponame_str |
Repositório Institucional da UFG |
collection |
Repositório Institucional da UFG |
bitstream.url.fl_str_mv |
http://repositorio.bc.ufg.br/tede/bitstreams/4cff681b-f718-47b0-9b8c-74a7371e2fda/download http://repositorio.bc.ufg.br/tede/bitstreams/c3d015cc-5a84-4b7b-8d1c-b030959b0c79/download http://repositorio.bc.ufg.br/tede/bitstreams/22e35d1d-a4fb-4bd0-951c-72f3cd13f669/download http://repositorio.bc.ufg.br/tede/bitstreams/bb8001ed-d48c-4484-b66d-f556f827e632/download http://repositorio.bc.ufg.br/tede/bitstreams/3ba90b6d-74ad-4dfb-8112-f3820af79f14/download |
bitstream.checksum.fl_str_mv |
bd3efa91386c1718a7f26a329fdcb468 4afdbb8c545fd630ea7db775da747b2f d41d8cd98f00b204e9800998ecf8427e d41d8cd98f00b204e9800998ecf8427e 6c2c1f811c32328fc8cdb22d9edaf90a |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFG - Universidade Federal de Goiás (UFG) |
repository.mail.fl_str_mv |
tasesdissertacoes.bc@ufg.br |
_version_ |
1798044329385656320 |